
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune is a clinical-stage biotechnology company with a strong pipeline of therapeutics and diagnostics targeting neurological disorders. Their innovative approach utilizing small molecules, antibodies, and vaccines specifically designed for protein misfolding diseases positions them to be a leader in this field. With positive clinical data and impressive financials, including a net loss decrease from the same period last year and a current cash position of CHF 74.8M, AC Immune is well positioned for success. Their partnerships with major pharmaceutical companies and diverse pipeline make AC Immune a promising investment opportunity.
Bears say
AC Immune is facing significant risks in its business operations, considering its focus on neurodegenerative diseases associated with protein misfolding. The company's pipeline is still in early stages, with no products currently approved for commercialization. Additionally, the company's high research and development costs and lack of diversification in its product pipeline could potentially hinder its financial stability.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares